ARVINAS, INC. Q3 FY2026 earnings call

• Strategic Focus: Management reaffirmed commitment to data-driven capital allocation, prioritizing programs with emerging evidence for value creation.
• ARV-393 (BCL6 Degrader): Submitted initial monotherapy dose escalation data for presentation at ASH in December 2026, focusing on T-cell lymphomas. A second readout is expected mid-2027, including B-cell data and combination results with glufidamab.
• ARV-027 (PolyQAR Degrader/SBMA): Phase I trial advancing; healthy volunteer data expected H1 2027, with patient dosing beginning H1 2027. Targeting ~50% reduction in PolyQAR to rescue muscle strength.
• ARV-6723 (HPK1 Degrader): First-in-class immuno-oncology asset initiated Phase I in Q3 2026. Monotherapy ongoing; combination with pembrolizumab planned for H1 2027. Initial data expected H2 2027.
• ARV-102 (LRRK2 Degrader): Prioritizing Phase 1b trial in EU/UK for Progressive Supranuclear Palsy (PSP), targeting initiation in 2027. US FDA discussions ongoing regarding clinical hold for Parkinson’s disease (PD).
• Financial Discipline: Reduced G&A by 40% YoY ($12.6M vs $21M) and R&D by 28% YoY ($46.9M vs $64.7M). Ended Q3 2026 with $558.9M in cash, projecting runway into H2 2028.

Arvinas operates as a single clinical-stage biopharmaceutical entity focused on protein degradation. There are no distinct product segments generating independent revenue streams to report in absolute terms or as a percentage of total revenue. The company reported its first royalty revenue of $0.5 million from the Rigel license agreement, which is categorized under revenue with associated costs recorded in the cost of license revenue line. All other financial metrics reflect consolidated operating expenses for the development portfolio.

• Clinical Milestones:
  • ARV-393: Data disclosure at ASH (Dec 2026); second readout mid-2027.
  • ARV-027: Healthy volunteer and SBMA patient data H1 2027.
  • ARV-6723: Initial data H2 2027; combination dosing H1 2027.
  • ARV-102: Phase 1b CTA submission next month; trial initiation 2027.
• Financial Runway: Cash resources sufficient to fund key clinical milestones through the second half of 2028.
• Capital Allocation: No specific upward/downward revisions to financial guidance provided; emphasis on maintaining cash efficiency while funding current pipeline.

• Regulatory Delays: Ongoing FDA clinical hold for ARV-102 in the US may delay US patient enrollment, though EU/UK trials are proceeding.
• Clinical Failure Risk: Early-phase data (especially low-dose efficacy signals) may not translate to robust responses in larger populations or later stages.
• Competition: Intense competition in BCL6 and neurodegenerative targets; need to demonstrate superiority or differentiation against existing therapies.
• Rare Disease Challenges: Small patient pools for SBMA and PSP limit trial speed and statistical power.
• Partnership Dependency: ARV-806 (KRAS G12D) program requires a partner to advance; no internal progression planned.

Q: What are the specific criteria for moving from healthy volunteers to SBMA patients in the ARV-027 trial, and does hitting the 50% degradation threshold gate this transition? / A: Management clarified that there is no gating requirement based on achieving a specific degradation level in healthy volunteers. The multiple-dose healthy volunteer study aims to identify a safe, bioavailable dose for subsequent patient dosing. Given the rarity of SBMA, the team will transition to patient cohorts once safety and tolerability are established, rather than waiting for precise biomarker thresholds, to preserve scarce patient samples for registrational trials.

Q: How should investors interpret the early efficacy signals in ARV-393, particularly given that initial doses are below predicted efficacious levels for B-cell lymphoma? / A: Management noted that the first data disclosure focuses on T-cell lymphoma, where even modest response rates (above 30%) would be encouraging given the unmet need and low doses used. For B-cell lymphoma, the modeling assumes lower efficacy at these early doses. Investors should expect more informative B-cell data, including durability and combination effects, in the mid-2027 readout when higher, efficacious doses are tested.

Q: What is the strategic rationale for initiating the ARV-102 Phase 1b trial in the EU/UK instead of the US, and how does this impact the registration timeline? / A: The decision is driven by multifactorial regulatory differences, specifically regarding chronic toxicology requirements and ongoing FDA conversations about the clinical hold. By launching in Europe, Arvinas can accelerate proof-of-concept data generation in 2027. The US may be included in future global registration efforts once the Phase 1b establishes safety and PK/PD confidence, rather than delaying all progress for US clearance.

Q: What are the expectations for the ARV-6723 HPK1 degrader in the context of next-generation IO agents like PD-1/VEGF combinations? / A: Management views HPK1 as a complementary mechanism acting on innate immunity and tumor microenvironment remodeling, distinct from T-cell exhaustion pathways targeted by PD-1. They do not see it as direct competition but as a potential backbone for combination strategies. Preclinical data show activity in checkpoint-resistant models, supporting its use post-checkpoint inhibitor or in combination to enhance broader immune activation.